Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014.

Cash and investments in marketable securities at June 30, 2014 were $301.4 million as compared to $309.1 million at March 31, 2014."The second half of 2014 will be an exciting time for Nektar as we look forward to significant milestones for a number of our late-stage clinical programs," said Howard W. Robin, President and Chief Executive Officer of Nektar. "The first of these is the potential US and EU approvals of Movantik™ with our partner AstraZeneca. If approved, Movantik would be the first oral targeted therapy approved for opioid induced constipation, a debilitating condition that occurs in up to 80%* of the 69 million chronic pain patients worldwide. Our partner Baxter has completed dosing in their Phase 3 study for BAX 855, a longer-acting PEGylated Factor VIII therapy to treat hemophilia A and plans to file the BLA in the U.S. by the end of this year. In our proprietary pipeline, we are on track for topline results from the Phase 3 breast cancer study for NKTR-102 in Q1 2015."

Revenue in the second quarter of 2014 was $28.5 million as compared to $33.9 million in the second quarter of 2013. Year-to-date revenue for 2014 was $48.3 million as compared to $56.9 million in the first half of 2013.  The decrease in revenue in the second quarter and first half of 2014 as compared to the same periods in 2013 is primarily due to decreased manufacturing activity.  Revenue included non-cash royalty revenue, related to our 2012 royalty monetization, of $4.8 million and $10.6 million in the second quarter and first half of 2014, respectively, and $3.8 million and $8.2 million in the second quarter and first half of 2013, respectively. This non-cash royalty revenue is offset by non-cash interest exp
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- In the Friday, December 19 edition of USA ... Technology (HIT) features Konica Minolta, the company announced today. The supplement ... leading healthcare organizations. In addition to the print ... as New York , Chicago ... Minneapolis and San Francisco ...
(Date:12/19/2014)... 19, 2014 TODAY, AEGATE, the ... World announced the appointment of Peter Fox ... Chief Channels and Partner Officer. Peter has ... to its acquisition by Oracle in 2011. ... Geneva and subsequently Convergys, a world ...
(Date:12/19/2014)... , Dec. 19, 2014  Newport Corporation (NASDAQ: ... Kadia, Ph.D. has joined the company,s Board of ... Officer and a director of Evans Analytical Group, ... evaluation and analytical services to companies in a ... to joining Evans Analytical Group, Dr. Kadia spent ...
Breaking Medicine Technology:USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... Amarin Corporation plc (Nasdaq: AMRN ) ... on cardiovascular disease, today announced that, in connection with ... Shares ("ADSs"), the underwriters of the offering have exercised ... aggregate of 1,800,000 additional ADSs to cover over-allotments.  The ...
... 7, 2011 Echo Therapeutics, Inc. (OTC Bulletin Board: ... Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous ... transdermal drug delivery, today announced that Patrick T. Mooney, ... Echo Therapeutics will present at the OneMedForum 2011 annual ...
Cached Medicine Technology:Amarin Announces Underwriters' Exercise of Over-Allotment Option 2Amarin Announces Underwriters' Exercise of Over-Allotment Option 3Amarin Announces Underwriters' Exercise of Over-Allotment Option 4Echo Therapeutics to Present at the OneMedForum 2011 Conference 2
(Date:12/19/2014)... intestinal bacteria that cause inflammatory bowel disease, which includes ... report. The findings, published recently in the journal ... prevent the disease and treat the 1.6 million Americans ... "The intestinal bacteria, or ,gut microbiome, you develop at ... on your health for the rest of your life," ...
(Date:12/19/2014)... -- The cost of cancer treatment can cause financial ... Researchers examined data from 1,000 people in the ... lung cancer. Of those patients, almost 900 had finished ... had advanced cancer. Nearly half of the patients ... which was linked with a poorer health-related quality of ...
(Date:12/19/2014)... 19, 2014 B. E. Smith, the ... providers, has been retained to lead a national ... Center in Estes Park, Colo. The top executive search ... recently placed more than 900 healthcare executives into organizations. ... 25-bed, not-for-profit critical access hospital and level IV trauma ...
(Date:12/19/2014)... Pain Free Living a leader in the ... new Superior magnetic necklace using ion neodymium ... neodymium magnets for the fastest pain relief in a ... Magnetics brand for the fastest relief by using 5200 ... using Superior Magnetic Jewelry at fairs and festivals” explained ...
(Date:12/19/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... , Firstly, the report provides a basic overview of ... Then, the report explores the international and Chinese major ...
Breaking Medicine News(10 mins):Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:New Superior Magnetic Necklace Relieves Migraine Headache 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6
... $18 million research program headed by Washington University ... and diagnostic tools for heart and lung diseases ... Heart, Lung, and Blood Institute, will fund five ... collaborating,institutions: Texas A&M University, University of Texas Southwestern ...
... The Alzheimer,s Association has awarded a three-year, $200,000 ... The University of Texas Health Science Center at Houston ... Alzheimer,s disease. "The main goal of this project ... such as a blood test that can tell people ...
... A team of researchers led by a Michigan State University ... for breast cancer in young women, focusing on growth, diet, ... The five-year study, funded by the National Institutes ... of Human Medicine,s Department of Epidemiology, will include the largest ...
... traumatic event a car accident, a physical or ... many as 1 in 5 children will develop Posttraumatic ... helps improve communication between child and caregiver, such as ... skills, was able to prevent chronic and sub-clinical PTSD ...
... Minn. -- In the largest, most modern, single-institution ... a long-term data registry for survival rates of ... for localized prostate cancer. The findings are being ... American Urological Association,s 84th Annual Meeting in Chicago. ...
... HealthDay Reporter , TUESDAY, Sept. 28 (HealthDay News) -- ... proteins may indicate the presence of prostate cancer more accurately ... The test, which has thus far only been assessed ... fewer false-positive results than the prostate specific antigen (PSA) test, ...
Cached Medicine News:Health News:WUSTL awarded $18 million to treat heart, lungs with nanotechnology 2Health News:WUSTL awarded $18 million to treat heart, lungs with nanotechnology 3Health News:MSU researcher awarded $14 million to identify breast cancer risk factors 2Health News:After traumatic event, early intervention reduces odds of PTSD in children by 73 percent 2Health News:Surgery offers long-term survival for early stage prostate cancer patients 2Health News:Experimental Test May Spot Prostate Cancer Earlier, More Accurately 2Health News:Experimental Test May Spot Prostate Cancer Earlier, More Accurately 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: